Introduction
Molecular analysis of chromosomal translocations has contributed to identification of the genes involved in oncogenesis in human cancers. Such genes encode proteins which normally function to control cell growth, differentiation or survival. Recent studies have revealed that structural alterations or inappropriate expressions of these genes often result in the blocking of cellular differentiation, thus leading to leukemogenesis. 1, 2 The t(3;5)(q25.1;q34) chromosomal translocation is associated with myelodysplastic syndrome (MDS), and occurs in all FAB morphological subtypes of AML, except for M3. Trilineage dysplasia is commonly observed in bone marrow with t(3;5), and an early relapse and refractory disease are characteristic of patients with the translocation. 3 The chimeric gene specific for t(3;5) was cloned, showing a nucleophosmin (NPM) on chromosome 5 fused to a novel protein, myelodysplasia/myeloid leukemia factor 1 (MLF1), on chromosome 3. 4 NPM is a highly conserved, ubiquitously expressed RNA-binding nucleolar phosphoprotein. One of its functions is thought to be the shuttling of ribonucleoproteins between the nucleolus and cytoplasm. [5] [6] [7] [8] The function of MLF1 is unclear because it has no significant similarity of amino acid sequences to known proteins. However, we recently reported that the NPM-MLF1 chimeric protein has the ability to induce apoptosis with slower kinetics than wellknown proto-oncogenes like c-myc. Analyses with deletion mutants revealed that the N-terminus of MLF1 contains a novel domain inducing apoptosis. 9 Also, a murine homolog of MLF1 has been isolated as one of the genes involved in lineage switching from erythroleukemic cells to hematopoietic cells of a monocytic/macrophage phenotype. 10 These findings strongly suggest that MLF1 is involved in lineage determination by regulating an apoptotic pathway.
To date, the involvement of NPM has been reported in three types of chromosomal translocations, t(2;5), t(5;17) and t(3;5). The t(2;5) translocation is observed in non-Hodgkin's lymphomas, in which NPM is fused to a novel receptor tyrosine kinase ALK. 11 The t(5;17) is a rare translocation found in acute promyelocytic leukemia and produces a chimeric protein between NPM and a retinoic acid nuclear receptor (RAR␣). 12 These three translocations are classified as having totally different clinical properties, which suggests that the altered functions of the C-terminal proteins determine the phenotype of malignancy in translocations involving NPM. It is conceivable that investigation of the pattern of MLF1 expression in normal and malignant hematopoietic cells would provide further insights into the mechanism of oncogenesis. To address this possibility, we examined the expression of MLF1 transcripts in 109 samples of patients with AML or MDS, as well as CD34 + and lineage-specific populations of normal hematopoietic cells.
Materials and methods

Clinical samples and cell preparation
One hundred and twenty-seven bone marrow (BM) samples or peripheral blood (PB) samples from 124 consecutive patients, made up of 65 patients with AML including 12 patients transformed from MDS (post-MDS AML), 44 patients with MDS and 18 patients with ALL, were obtained with informed consent. Patients with AML and MDS were classified according to the French-American-British (FAB) criteria. 13, 14 MDS patients were diagnosed as post-MDS AML when greater than 30% of blasts became detectable in the bone marrow and peripheral blood during observation. In this study, none of the AML and MDS patients had the t(3;5) chromosomal translocation. AML patients were also treated with combination chemotherapy, consisting of cytosine arabinoside (or behenoyl cytosine arabinoside), daunorubicin, idarubicin and/or 6-mercaptopurine, while AML-M3 patients were treated with all-trans retinoic acid for remission induction therapy. Mononuclear cells (MNC) from heparinized PB and BM cells were separated by Lymphoprep (Nycomed, Oslo, Norway) density gradient centrifugation and frozen as pellets or in 10% dimethyl sulfoxide for further study.
Normal PB cells or BM aspirates were obtained from healthy volunteers or BM transplantation donors, respectively, with informed consent. CD34
+ cells were purified from bone marrow MNC with a magnetic cell sorting (MACS) CD34
+ isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), and the magnetically labeled cells were enriched with a Mini MACS column system (Miltenyi Biotec) according to the manufacturer's instructions. GlycophorinA
+ or CD14 + cells were sequentially separated from CD34 − cells using the same isolation system. More than 94% purity in each population was obtained with this system. CD61
+ cells were directly separated from bone marrow MNC with this system. Purity of CD61
+ cells was much lower than expected because activated CD61
+ platelets form aggregates with matured monocytes. Therefore, primary megakaryocytes were identified morphologically and confirmed with immunohistochemical staining with an antibody to CD61.
Granulocytes were separated from normal peripheral blood cells by density gradient centrifugation with a Mono-Poly Resolving medium (Dainippon Pharmaceutical, Osaka, Japan).
Northern blot analysis
RNA was extracted from the frozen pellets of PB and BM samples and cell lines by the acid guanidinium thiocyanatephenol-chloroform method 15 using TRIzol (GIBCO BRL, Grand Island, NY, USA). Total RNAs (40 g per lane) were separated by electrophoresis in 1% agarose gels containing 2.2 M formaldehyde and transferred to nylon membranes (Amersham, Buckinghamshire, UK). After UV cross-linking (Stratagene, La Jolla, CA, USA), the membranes were hybridized with a 252 bp SacI fragment of MLF1 cDNA or ␤-actin cDNA labeled with ␣-32 P dCTP at 42°C overnight and washed at an appropriate stringency at 56°C. 4 Exposure to Xray films (Eastman Kodak, Rochester, NY, USA) was performed at −80°C for 3 days. Developed films were quantitatively analyzed with a densitometer DMU-33C (Advantec Toyo, Tokyo, Japan).
RT-PCR
RT-PCR was performed as described. 16 Single-stranded cDNA was synthesized from 2.0 g of total RNA with random hexamers and 10 U of Rous-associated virus 2 reverse transcriptase (Takara, Kyoto, Japan) in 50 l of reaction mixture at 42°C for 60 min. PCR reactions were performed with oligonucleotide primers specific for the coding sequences of MLF1 (5ЈMLF1, 5Ј-TCGTTTTTCCAATCTGTCCGC-3Ј; and 3ЈMLF1, 5Ј-GATACTGAGCAAGTCTCTTCC-3Ј) 4 and with a set of primers for the ␤-actin gene as a control (5Ј␤-actin, 5Ј-GAAATCGTGCGTGACATTAAG-3Ј, and 3Ј␤-actin, 5Ј-CTA-GAAGCATTTGCGGTGGACGATGGAGGGGCC-3Ј). A PCR buffer (90 l) containing 2.5 U Taq polymerase (Takara) and 0.5 mol/l of the 5Ј and 3Ј primers was added to 10 l of the RT reaction mixture. For detection of MLF1, the mixture was amplified using a thermal cycler (Perkin Elmer-Cetus, Norwalk, CT, USA) for each cycle, with denaturation at 94°C for 60 s, annealing at 60°C for 60 s and extension at 72°C for 60 s. The conditions for ␤-actin amplification included each cycle consisting of denaturation at 94°C for 60 s, annealing at 61°C for 60 s and extension at 72°C for 60 s.
Quantitation of the PCR products for MLF1 expression
Fifteen microliters of PCR products were electrophoresed in a 3% NuSieve agarose gel (FMC Bioproducts, Rockland, ME, USA) containing 0.05 g/ml ethidium bromide, and photographed under UV light with Polaroid 665 film (Polaroid, Cambridge, MA, USA). The negative film was developed for 5 min at 25°C, washed with running water for 5 min and quantitatively analyzed with a densitometer DMU-33C. The ratio of MLF1/␤-actin (expression ratio) in HEL cells was calculated as 1.0.
Production of Anti-MLF1 monoclonal antibodies
Balb/c mice were injected peritoneously with 0.38 mg of His-tagged MLF1 recombinant protein emulsified in Freund's adjuvant. Two further immunizations of 0.19 mg recombinant protein in phosphate-buffered saline (PBS) were administrated at 14 day intervals. Three days after a fourth injection of 0.1 mg recombinant protein, hyperimmune spleen cells were fused with the P3-X63-Ag8-U1 myeloma cell line in the presence of 50% polyethylene glycol. Initial screening was performed using the enzyme-linked immunosorbent assay (ELISA) technique against the recombinant His-tagged MLF1 protein.
Further screening to determine specificity was performed using immunofluorescence staining and immunoblotting analysis on transfected cells with MLF1 or NPM-MLF1. Among several positive clones successfully isolated, one clone (3E9) was chosen because of high specific reactivity and very low background in immunofluorescence staining, immunoprecipitation and immunoblotting.
Western blot analysis and immunohistochemistry
To prepare direct lysates for immunoblotting, cells were lysed in an SDS-sample buffer (40 mM Tris-HCl, pH 6.8, 0.1 m DTT, 1% SDS, 10% glycerol, and 0.05% bromophenol blue) and boiled for 4 min. Equal amounts of the cell lysates clarified by centrifugation were analyzed by immunoblotting. MLF1 was detected with an anti-MLF1 monoclonal antibody (MoAb), clone 3E9.
Cells were cytocentrifuged on to a slide for immunohistochemical staining and incubated with anti-MLF1 MoAb for 30 min. The streptavidin-biotin-peroxidase complex (ABC) method (DAKO, Tokyo, Japan) was used according to the manufacturer's instructions. The peroxidase reaction was developed using diaminobenzidine tetrahydrochloride and hydrogen peroxide. The slides were counterstained with hematoxylin before mounting.
Statistics
Mann-Whitney's test was used to calculate significant differences (P Ͻ 0.05) of MLF1 mRNA expression between various groups for clinical factors. Survival curves of patients with high (Ͼ0.4) or low (Ϲ0.4) level MLF1 expression were estimated by the Kaplan-Meier method, and statistical analysis of the difference between the survival curves was performed using the generalized Wilcoxon's and log-rank tests. Multivariate analysis of the prognosis was performed using Cox's proportional hazard regression model.
Results
Determination of optimal conditions for quantitative RT-PCR
Optimal conditions for RT-PCR for the MLF1 expression were determined with cDNA from HEL cells, 17 in which the expression level was almost equal to the highest of the clinical samples. When cDNA prepared from 60 ng of total RNA from HEL cells was amplified with sequential cycles, exponential amplification was plotted at 25 to 31 cycles for MLF1 and at 18 to 22 cycles for ␤-actin (Figure 1a) . Amplification of serially diluted cDNAs under conditions of 31 cycles for MLF1 and 22 cycles for ␤-actin was linearly plotted in a range from 1.875 to 90 ng of total RNA (Figure 1b) . Therefore, patients' samples were subjected to quantitation at 31 cycles for MLF1 and 22 cycles for ␤-actin with cDNA derived from 60 ng of total RNA. The relative expression level of MLF1 was evaluated from the ratio of MLF1/␤-actin by defining HEL as 1.0.
Correlation between the levels of MLF1 expression quantitated by RT-PCR and Northern blot analysis in fresh samples or normal blood cells
Based on the results obtained from the HEL cell line, we tested for MLF1 expression in a small amount of fresh sample, Figure 2b . Four RT-PCR products of MLF1 were detected with a pair of primers designed to span a position identical to the breakpoint of the NPM-MLF1 chimeric gene, where the three alternatively spliced forms of MLF1 contain additional short exons of 44 bp, 73 bp or both 44 bp plus 73 bp. However, only the shortest form which contains no inserted short exons is able to encode a protein. 4 The RT-PCR products of MLF1 and ␤-actin were digested with the appropriate restriction enzymes to confirm the specificity of amplification. For the MLF1 products, a XmnI restriction site common to four alternative splicing forms was used. The ␤-actin products were digested with AfaI to four fragments. The expected sizes of digested fragments were obtained ( Figure  2c ). Strong signals were observed in samples isolated from AML (M6) or post-MDS AML patients by both methods. MLF1 transcripts were not detectable in normal PB or normal BM cells by Northern blot analysis, whereas a very low level of MLF1 expression was detected by quantitative RT-PCR. Using a densitometer, we measured the relative amounts of MLF1 mRNA in these 14 samples independently, and found a strong positive correlation between the data obtained by these two methods (correlation coefficient, r = 0.974) (Figure 2d ). MLF1 protein expression in the above cells was confirmed by immunoblotting with anti-MLF1 monoclonal antibody, clone 3E9, which we recently generated. The expected size of a protein for MLF1 (31 kDa) was detected in lysates from representative mRNA-positive patients' cells as well as HEL cells (Figure 2e ). Further studies with cell lines showed that the level of protein expression significantly correlated with that of the shortest form of only the RT-PCR products which encoded a protein (data not shown). Therefore, we decided to extend the study to a large number of clinical samples, including those of AML and MDS, by the quantitative RT-PCR method. Subsequently, only the shortest form of the RT-PCR products of MLF1 was subjected to quantitation, reflecting the level of protein expression.
Normal expression pattern of MLF1 in hematopoietic cells
Using the RT-PCR method, we first examined which populations of normal hematopoietic cells expressed MLF1 transcripts. CD34
+ or CD14 + cells were sequentially separated from normal bone marrow MNC using a magnetic cell sorting system. Granulocytes were separated from normal peripheral blood cells. MLF1 transcripts were dominantly expressed in CD34 + cells, but only slightly in GlyA tive for MLF1 staining (Figure 3b ). These facts indicate that the expression of MLF1 in CD34 + progenitor cells decreases during differentiation to each lineage. Figure 4 . In this study, over 0.4 was defined as a significantly elevated level of MLF1, because an expression ratio of mRNA over 0.4 was equivalent to the level that was detectable by Northern blot analysis and protein analysis. Among AML, high levels of MLF1 expression (over 0.4) were observed in some patients with relatively immature AML (M1 and M2), erythroblastic/magakaryoblastic AML (M6 and M7) and post-MDS AML, while AML (M3 and M4) cells expressed less MLF1 transcripts than other AML cell subtypes (Figure 4) . Although patients' samples contained highly variable numbers of blasts (40-96% of MNC), there was no difference in the average and range of blast counts between the high MLF1 mRNA expression patients and others (data not shown). Interestingly, three of 12 AML samples diagnosed as post-MDS showed high levels of MLF1 expression. Statistical significance of MLF1 levels was observed in post-MDS compared to normal cases (normal PB and BM, n = 14) and de novo AML (n = 53) (P = 0.002 and P = 0.023, respectively). In contrast to AML, the level of MLF1 expression in the low risk group of patients with MDS (RA and RARS) was as low as that of normal BM cells, and a high level of MLF1 expression was observed in the high risk group of patients with RAEB and RAEB-T. Statistically, the average of MLF1 levels in patients with RAEB and RAEB-T was significantly higher than that of normal cases (P = 0.046 and P = + cells were positive in the cytoplasm as well as the positive control HEL cells (top row), whereas normal primitive megakaryocytes (second row, right, shown by arrows) and the negative control HL60 cells (second row, left) were negative. Primary megakaryocytes were isolated with CD61 + microbeads, identified morphologically from contaminated matured monocytes, and confirmed with CD61 antibody staining.
Expression of MLF1 in fresh samples with AML and MDS
Leukemia 0.002, respectively). The average level of MLF1 expression in the high risk MDS (RAEB and RAEB-T, n = 25) was also higher than that in the low risk MDS (RA and RARS, n = 15) (P = 0.034). In three cases with transformation to RAEB-T or overt leukemia, MLF1 expression increased during transformation as shown by arrows (Figure 4) .
Relationship between MLF1 expression and clinical factors
Precise clinical records in all 65 patients with AML and 38 of 44 of those with MDS were available to evaluate the correlation with the level of MLF1 expression. Several factors are listed in Table 1 . The level of MLF1 expression did not relate to age, gender, WBC counts, Hb, or platelet counts (data not shown), whereas the t(15;17) specific for M3 subtype and −7, +8 or/and 5q− often observed in MDS and MDS-related AML exhibited negative and positive correlations to the level of MLF1, respectively. However, many MDS cases harbor more than two chromosomal aberrations, which makes accurate statistical analysis difficult. The clinical features in 14 cases with high MLF1 expression are summarized in Table 2 , where unfavorable response to initial chemotherapy and poor prognostic chromosomal aberrations related to MDS were characteristic.
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Prognosis of patients with AML and MDS expressing MLF1
To examine whether a high level of MLF1 expression could affect the prognosis of patients with AML and MDS, the patients were divided into two groups with a cut-off point of 0.4 for univariate analysis. Seven of 65 patients (11%) with AML exhibited a ratio of mRNA over 0.4. All 65 cases were treated with the protocol proposed by the Japan Adult Leukemia Study Group, 21 or modified protocols, and were followed in our or a collaborating institute for more than 2 years. The high-level expression group had significantly lower rates of overall survival (Figure 5a , P = 0.0250, generalized log-rank test, P = 0.0414, Wilcoxon's test). In MDS, seven of 44 patients (16%) with high levels of MLF1 expression (ratio of mRNA over 0.4) had a poor prognosis and there was a distinct difference in survival time between the two groups (Figure 4b , P = 0.0028, generalized log-rank test, P = 0.0081, Wilcoxon's test). Significance was also obtained using the Cox's proportional hazard regression model in univariate analysis, with a hazard ratio of 2.71 (P = 0.049; 95% confidence intervals (CI), 1.02 to 7.35) for AML and that of 3.91 (P = 0.006; 95% CI, 1.46 to 10.44) for MDS calculated for patients with high levels of MLF1 expression (Ͼ0.4) compared with those with low levels (р0.4). Based on the international prognostic scoring system for MDS, we examined whether several major prognostic factors including BM blast (%), cytogenetics, cytopenias, age, and gender influence the independence of MLF1 level on overall survival in multivariate analyses. Among them, the confounding variables were chromosomal aberrations (−7, +8 or/and 5q−: yes vs no, P = 0.248; 95% CI, 0.65 to 5.41) for AML and BM blast (%) (Ͻ5% vs у5%, P = 0.06; 95% CI, 0.96 to 7.11), and chromosomal aberrations (good vs intermediate and poor, P = 0.106; 95% CI, 0.82 to 8.05) for MDS. Thus, as shown in Table 2 , the fact that most cases with high MLF1 expression were classified with high risk MDS-related clinical characteristics was a major reason for poor prognosis.
Discussion
The translocation of the MLF1 gene into the NPM coding region appears to be a key event in the pathogenesis of unique MDS-associated acute myeloid leukemia harboring t(3;5). 4 In the present study, we showed that significantly elevated levels of non-translocated MLF1 expression were observed in t(3;5)-negative myeloid cell malignancies with a high frequency. The clinicopathological features found in patients exhibiting high levels of MLF1 expression are compatible with those of patients harboring t(3;5). Moreover, MLF1 was normally expressed in the population of CD34
+ hematopoietic progenitor bone marrow cells, but slightly expressed in glycophorin A+ erythrocytes, megakaryocytes, monocytes, granulocytes or lymphocytes. The mechanism of MLF1 upregulation in immature AML, high risk MDS and post-MDS AML is unknown, but our data and clinical findings of t(3;5)-positive AML suggest that MLF1 normally functions during the differentiation of progenitor cells and that dysfunction of MLF1 plays a role in malignant transformation of t(3;5)-negative AML and MDS.
We recently reported that ectopic expression of NPM-MLF1 chimeric protein induced apoptotic cell death with slower kinetics in proliferating K562 human erythroleukemic cells and serum-starved NIH3T3 mouse fibroblast cells. NPM-MLF1-mediated apoptosis required the N-terminal domain of MLF1, dimerization and nuclear/nucleolar transportation of the protein, which indicates that MLF1 itself is involved in the pathway. Co-expression of Bcl-2 rescued NIH3T3 cells from NPM-MLF1-mediated cell death and enabled the cells to progress into the S phase in low serum, implying that sequential activation of NPM-MLF1 and anti-apoptotic proto-oncogenes could collaboratively contribute to malignant transformation. 9 These facts also suggest that NPM-MLF1 affects a certain G1 regulator in the cell cycle progression from the G1 phase to the S phase. In fact, we found that K562 cells expressing NPM-MLF1 had obviously decreased protein levels of the endogenous p27 KIP1 cyclin-dependent kinase inhibitor. 22 Although mutations in p27 are rarely found in human tumors, reduced expression of the protein correlates directly with both histological aggressiveness and poor survival in patients with various tumors. [23] [24] [25] [26] Our finding that deregulation of the MLF1 signaling pathway by producing NPM-MLF1 leads to p27 downregulation indicates that MLF1 may function upstream of p27. Thus, it is likely that mutations or aberrant overexpression of MLF1 and/or MLF1 interacting proteins are involved in the leukemogenesis from MDS by disrupting the p27 regulatory mechanisms of cell cycle control. We are currently investigating the mechanism of p27 downregulation through the MLF1 signaling pathway by analyzing MLF1 interacting protein.
In addition, a murine homolog of MLF1 was reported as a hemopoietic lineage switch (HLS) 7 which influenced erythroid/myeloid lineage switching and development of normal hematopoietic cells. Ectopic expression of HLS7 induced a monoblastoid phenotype in J2E murine erythroleukemic cells without impeding the intracellular erythropoietin signaling pathway and promoted maturation of M1 monoblastoid cells or myeloid colony formations from normal primitive hematopoietic cells. 10 
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In conclusion, all these findings suggests that MLF1 plays a role in the very early stage of hematopoiesis, and that a malfunction in the MLF1 signaling pathway disrupts normal hematopoietic cell development ultimately leading to malignant transformation of cells. The detailed molecular function of MLF1 remains to be determined, but a good correlation between increased MLF1 levels and MDS-associated malig-
Figure 5
Survival curves of AML patients and MDS patients. (a) In AML, high MLF1 (Ͼ0.4) patients (n = 7, --) had a worse prognosis than low MLF1 (р0.4) patients (n = 58, ---) (generalized log-rank test, P = 0.0250 and Wilcoxon's test, P = 0.0414). (b) Survival curves of MDS patients. High MLF1 (Ͼ0.4) patients (n = 7, --) had a worse prognosis than low MLF1 (р0.4) patients (n = 37, ---) (generalized log-rank test, P = 0.0028 and Wilcoxon's test, P = 0.0081).
nancy definitively provides new insights into leukemogenesis from MDS.
